Lacey David L. 4

What Happened

• David L. Lacey, a director of Nurix Therapeutics, was granted an award for 31,250 derivative shares (transaction code A) on 2026-05-15. The reported acquisition price is $0.00, and the award is recorded as a derivative security (not an immediate open-market purchase or sale).

Key Details

• Transaction date: 2026-05-15; Filing date: 2026-05-15 (filed same day).
• Shares/units granted: 31,250 derivative shares; reported price: $0.00.
• Shares owned after transaction: not specified in the supplied Form 4.
• Footnote: The award vests 100% on the earlier of (a) the next annual meeting of stockholders or (b) May 15, 2027, provided the reporting person remains in service on the vesting date.
• No indication of a sale, cashless exercise, tax withholding, or 10b5-1 plan in this filing.

Context

• This is a grant/award (vesting-based derivative), which typically compensates or aligns directors with shareholder interests; it does not reflect an immediate purchase or sale of common stock. The award will only convert to vested shares if the vesting condition (continued service) is met.